Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Indication: Belzutifan for Advanced Pheochromocytoma or Paraganglioma
In the phase 2 LITESPARK-015 trial, Belzutifan demonstrated antitumor activity in advanced pheochromocytoma or paraganglioma with an objective response rate of 26%. The responses w
New Protocol: Capivasertib with Abiraterone for PTEN-Deficient Prostate Cancer
Capivasertib plus abiraterone showed a significant improvement in radiographic progression-free survival compared to placebo in patients with PTEN-deficient metastatic hormone-sens
New Indication: Adjuvant Atezolizumab for ctDNA-Positive Bladder Cancer
In this phase 3 trial, ctDNA-guided adjuvant atezolizumab improved both disease-free survival and overall survival in patients with muscle-invasive bladder cancer compared to place
New Drug: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
Disitamab Vedotin plus Toripalimab significantly improved progression-free and overall survival compared to chemotherapy in untreated HER2-expressing advanced urothelial cancer. Th
New Reference: Neoadjuvant Carboplatin for Triple-Negative Breast Cancer
This phase III trial evaluated the addition of carboplatin to neoadjuvant chemotherapy in triple-negative breast cancer. The addition improved overall survival, particularly in pre
New Reference: Nirogacestat for Desmoid Tumors
Long-term treatment with nirogacestat resulted in an objective response rate of 45.7%. Safety findings showed a decrease in the incidence and severity of treatment-emergent adverse
New Reference: Darolutamide for Non-Metastatic Castration Resistant Prostate Cancer
In this phase 3 trial, darolutamide significantly prolonged metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer compared to placebo, reducing t
New Reference: Pazopanib for Extrapancreatic Neuroendocrine Tumors
Pazopanib demonstrated activity in prolonging progression-free survival for advanced extrapancreatic neuroendocrine tumors. However, it was associated with an increased rate of sev
New Reference: Lenvatinib – Everolimus for Metastatic Clear Cell RCC
Lenvatinib plus everolimus prolonged progression-free survival compared to cabozantinib in patients with metastatic clear cell renal cell carcinoma that progressed on prior PD-1 in
